Loading quotes...
Forecast
There is no analyst data available for this company.
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Incannex Healthcare reports quarterly loss per share of $0.15
Incannex Healthcare reported earnings per share of -$0.15 for the quarter ended June 30, 2026, presented at the finance conference on September 25, 2026. For the fiscal year it reported a loss per share of -$1.66, after -$40.50 in the prior year. » More on finanzen.net
Incannex Healthcare receives AUD 6.04m tax credit and expects a further AUD 5.1m
Incannex Healthcare has received a payment of AUD 6,039,162.43 from the Australian research and development incentive program and expects additional tax credits of AUD 5.1 million in 2026. The expected total proceeds from this non-dilutive capital therefore exceed AUD 11.1 million. The funds are intended to support further development of clinical programs such as IHL-42X and PSX-001 and capital allocation measures, including a share buyback program. » More on de.investing.com
Incannex starts DReAMzz study to optimise dosing of IHL-42X for obstructive sleep apnea
Incannex has begun the clinical DReAMzz crossover study to optimise dosing of IHL-42X (dronabinol/acetazolamide) for the treatment of obstructive sleep apnea. The company lists 14 identified study centres, completed manufacturing of the investigational products, and secured import/export approvals and distribution agreements to activate the sites. IHL-42X has Fast Track status with the FDA; Incannex notes rapid cash burn despite positive balance-sheet metrics and says adequate funding is critical (market capitalization: $53.8m; share price: $3.90). » More on de.investing.com
Incannex reactivates stock buyback program after pause
Incannex resumed its stock buyback program after a period of inactivity over the last two trading days and says it will opportunistically continue repurchasing shares. The biopharmaceutical company reports about $75 million in cash following a financing round, is debt-free and shows a very high short-term liquidity ratio (Current Ratio 48.27). The stock trades at $3.41, below the InvestingPro fair value of $4.06; as of 31.12.2025 roughly $18.5 million remained available for buybacks. Incannex stresses the decision reflects a discrepancy between market valuation and its financial position as well as progress in the clinical pipeline (including IHL-42X, PSX-001). » More on de.investing.com
Incannex has about $75m in cash after financing round and is debt-free
Incannex has roughly $75 million in cash following a financing round led by institutional healthcare investors and carries no debt. Market capitalization is around $46 million, which together with the liquidity position results in a negative enterprise value. The proceeds are intended primarily to fund the phase‑2 dosing‑optimization study DReAMzz for IHL‑42X (obstructive sleep apnea); IHL‑42X has FDA Fast Track status. The company plans dose administrations in the coming months, has an approved share buyback program, and is concurrently advancing development of PSX‑001 (oral synthetic psilocybin). » More on de.investing.com
Financials
| (EUR) | 2023 | YoY |
|---|---|---|
| Revenue | 618.83k | 20.15% |
| Gross profit | 618.83k | 21.13% |
| Net profit | -12.19m | 122.65% |
| EBITDA | -10.79m | 361.24% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €8.73m |
Number of shares | 347.71m |
52-week high/low | €0.17 - €0.0251 |
| Dividends | No |
Beta | 2.09 |
P/E ratio | -2.88 |
PEG ratio | -0.03 |
P/B ratio | 0.37 |
P/S ratio | 0.00 |
Company profile
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
| Name | INCANNEX HEALTHCARE LTD. |
| CEO | Joel Bradley Latham |
| Headquarters | Sydney,
nsw Australia |
| Website | |
| IPO | 23/05/2007 |
| Employees | 3 |
Ticker symbols
| Exchange | Symbol |
|---|---|
Australian Securities Exchange Ltd | IHL.AX |